DSKYF (Daiichinkyo Co) Deferred Tax : $0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Daiichinkyo Co's change in deferred tax for the three months ended in Mar. 2025 was $0 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Mar. 2025 was $0 Mil.

Daiichinkyo Co Deferred Tax Historical Data

The historical data trend for Daiichinkyo Co's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Deferred Tax Chart

Daiichinkyo Co Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Deferred Tax

Get a 7-Day Free Trial

Daiichinkyo Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Deferred Tax	Get a 7-Day Free Trial															-	-	-	-	-

Daiichinkyo Co Deferred Tax Calculation

Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Daiichinkyo Co Deferred Tax Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSKYF) » Definitions » Deferred Tax

Comparable Companies

Traded in Other Exchanges

DSNKY:USA 4568:Mexico 4568:Japan D4S:Germany

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.